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Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai 410208, IndiaAbstractResveratrol has anti-inflammatory, cardio protective and cancer chemopreventive properties. The molecular targets for resveratrol in
early signaling cascades are not well understood. Resveratrol inhibits type II PtdIns 4-kinase but not PtdIns 3-kinase activity in vitro.
Resveratrol directly binds to the enzyme with a Kd of 7.2 mM. Kinetic studies show that resveratrol competes with PtdIns binding.
Inhibition of PtdIns 4-kinase activity by resveratrol/phenylarsine oxide reduces Jurkat cell adhesion to matrigel/fibronectin coated
surfaces, suggesting a role for type II PtdIns 4-kinase in lymphocyte infiltration to the sites of inflammation.
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Resveratrol is a naturally occurring stilbene (3,40,5-
trihydroxystilbene) synthesized by plants in response to
injury or fungal attack [1]. It exists in cis and trans
configuration. Trans resveratrol has been shown to pos-
sess many biological functions in in vitro and in animal
model systems. These include antioxidant activity, mod-
ulation of hepatic apolipoprotein and lipid synthesis,
inhibition of platelet aggregation as well as the produc-
tion of pro-atherogenic eicosanoids by human platelets
and neutrophils resulting in protection against athero-
sclerosis [2–5]. In addition to its cardio-protective activ-
ity, resveratrol has been implicated as chemopreventive
agent in carcinogenesis, through its actions on ribonu-
cleotide reductase activity, protein kinase C and Cdk
kinases [6–12]. Apart from these activities, resveratrol
is known to induce apoptosis through CD95 receptors in
tumor cell lines [13]. While most of these effects are theAbbreviations: PtdIns (4,5)P2, D-myo-phosphatidylinositol 4,5-bispho-
sphate; PtdIns 4P, D-myo-phosphatidylinositol 4-phosphate; PtdIns, D-myo-
phosphatidylinositolresults of long-term incubation of cells with resveratrol,
the early effects of resveratrol on cell signaling mechan-
isms are not well understood.
Resveratrol is shown to inhibit cell proliferation in
human peripheral blood lymphocytes and this inhibition
is due to an arrest of G0–G1 transition [14]. Phosphati-
dylinositol 4,5-bisphosphate (PtdIns (4,5)P2) hydrolysis
is an early and critical step in T cell proliferation and
differentiation, and very little is known about the effects
of resveratrol on PtdIns (4,5)P2 biosynthetic enzymes.
PtdIns (4,5)P2 is synthesized by sequential phosphoryla-
tion of PtdIns by PtdIns 4-kinases and PtdIns 4P-5-
kinases in the canonical pathway of PtdIns (4,5)P2 bio-
synthesis. PtdIns 4-kinases have been classified into
types II and III PtdIns 4-kinases. While type II PtdIns
4-kinases represent a new class of enzymes, type III
PtdIns 4-kinases share homology in their catalytic
domain with PtdIns 3-kinases [15,16]. A type II PtdIns
4-kinase activity has been suggested to be an integral part
of early signal transduction machinery in T cells stimu-
lated with polyclonal mitogen Con A or through TCR-
CD3 receptors [17–21]. The present manuscript describes
resveratrol as an inhibitor of type II PtdIns 4-kinase
without significant effects on PtdIns 3-kinase. 8
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2.1. Materials
Human type II PtdIns 4-kinase b clone (Gen Bank
accession #AY065990) was a generous gift from Tamas
Balla, Endocrinology and Reproduction Research Branch,
NICHD, Bethesda, MD, USA. Glutathione, thrombin and
glutathione sepharose beads were from Amersham Inter-
national plc. Phosphatidylinositol, Triton X-100, N-laur-
oylsarcosine, phenylmethyl-sulfonylflouride (PMSF),
resveratrol, fibronectin, matrigel and all restriction
enzymes were from Sigma, MO, USA or from Roche,
Germany. [g-32P] ATP was from Board for Radiation and
Isotope Technology (BRIT), Mumbai, India. All other
chemicals were of analytical grade. Primers used for
PCR was obtained from Microsynth, Switzerland.
2.2. Cloning of human type II PtdIns 4-kinase b
Human type II PtdIns 4-kinase was amplified using
PI4KF (forward) 50-TTATTGTCGACATGGAGGATCCC-
TCCG-30 and PI4KB (backward) 50-AAATAGCGGCC-
GCCCAGGAGGAAAAAAATGGCT-30 primers. The
amplified product was sub-cloned at SalI/ NotI sites in
pGEX-4T3 vector. The construct was expressed in
BL21(DE3) strain of E. coli using IPTG induction
(0.5 mM) at 37 8C for 3 h.
2.3. Purification of GST tagged protein
Bacterial cells expressing GST tagged proteins were
centrifuged at 14,700  g for 1 min. Bacterial cell pellet
was lysed in ice in STE buffer [10 mM Tris (pH 8.0), 1 mM
EDTA, 150 mM NaCl] and lysozyme at 100 mg/ml con-
centration (freshly prepared). After 15 min of incubation,
cells were sonicated for 1 min in presence of 10 mM DTT
and 1.5% N-lauroylsarcosine. The lysate was centrifuged
at 23,469  g for 20 min. The supernatant was diluted 1:1
with STE buffer and Triton X-100 to give a final concen-
tration of 0.7% N-lauroylsarcosine and 0.9% Triton X-100.
It was incubated for 30 min in ice. The lysate was added to
glutathione beads, that were prewashed with PBS (pH 7.6),
and incubated for 45 min at room temperature. The beads
were washed thrice with PBS. The washed beads were
incubated with thrombin protease for 4 h at 4 8C for
removal of GST tag. The purified protein was dialyzed
against PBS and analyzed on SDS–PAGE.
2.4. Resveratrol treatment of Jurkat cells
Jurkat cells (1  106) cells were washed twice with
serum free RPMI. The cells were suspended in 200 ml
of RPMI. Cells were incubated with different concentra-
tions of resveratrol for 45 min at 37 8C. Cells were washed
with PBS and lysed in 100 ml lysis buffer [25 mM Tris (pH7.4), 150 mM NaCl, 2 mM EGTA, 1% Triton X-100,
0.25 mM sodium orthovanadate, 1 mM PMSF]. The
lysates were assayed for PtdIns 4-kinase activity.
2.5. PtdIns 4-kinase assay
PtdIns 4-kinase assay was carried out in a final volume
of 50 ml containing 50 mM Tris (pH 7.6), 10 mM MgCl2,
0.25 mM EGTA, 0.1 mM sodium orthovanadate, 20 mg/ml
PtdIns, 100 mM (g-32P) ATP (200–300 cpm/pmol) and
0.3% Triton X-100. The reaction was initiated with the
addition of labeled ATP and incubated at room temperature
(25 8C) for 6 min. The reaction was terminated with
50 ml of 12N HCl. The labeled phospholipids were
extracted with 500 ml of chloroform:methanol:water
(15:5:5, v/v/v). The organic phase was washed with
100 ml of methanol:1N HCl (1:1, v/v) and applied on
Merck Silica gel tlc plates pretreated with 60 mM EDTA,
2% sodium potassium tartarate in 50% ethanol (pH 8.0).
The chromatograms were developed with chloroform:-
methanol:ammonium hydroxide:water (90:90:7:20, v/v/
v/v). The phospholipids were visualized by autoradiogra-
phy and quantified by scintillation counting [17].
2.6. Immunoprecipitation and PtdIns 3-kinase assay
Jurkat cells (10  106) were pelleted and lysed with
200 ml lysis buffer [25 mM Tris (pH 7.4), 150 mM NaCl,
2 mM EGTA, 1% Triton X-100, 0.25 mM sodium ortho-
vanadate, 1 mM PMSF]. Lysate was centrifuged at
13,000  g for 30 min. Supernatants were incubated with
1 mg of the antibody (p85, or p110) for 2 h at 4 8C. At the
end of this incubation, bovine serum albumin pre-coated
protein A agarose beads were added and incubated for 1 h
at 4 8C with gentle tumbling. The beads were washed 3
with PBS and 2 with lysis buffer without Triton X-100.
The beads were assayed for PtdIns 3-kinase activity in a
100 ml reaction volume containing 50 mM Tris (pH 7.6),
10 mM MgCl2, 0.25 mM EGTA, 0.1 mM sodium ortho-
vanadate, 20 mg/ml PtdIns, 100 mM (g-32 P) ATP (200–
300 cpm/pmol). The reaction was initiated with the addi-
tion of labeled ATP and incubated at room temperature
(25 8C) for 6 min. The reaction was terminated with
50 ml of 12N HCl. The labeled phospholipids were
extracted and separated as described previously for PtdIns
4-kinase assay. The phospholipids were visualized by
autoradiography and quantified by scintillation counting.
2.7. Resveratrol binding studies
Fluorescence studies were performed using a JASCO
fluorescence spectrophotometer. Spectra were taken by
multiple scans and buffer blanks were subtracted from
all measurements. A quartz cuvette of 3 mm path length
was used. The band pass for excitation and emission
monochromators was 10 nm. Emission spectra were
1050
Fig. 1. Resveratrol inhibits type II PtdIns 4-kinase activity in vitro. (A)
Type II PtdIns 4-kinase b was sub cloned and expressed in E. coli. The
expressed protein was purified and analysed on SDS–PAGE. (B) The effect
of resveratrol on type II PtdIns 4-kinase activity. Values are representative of
four experiments. Error bars represent standard deviation (S.D.). (C)
Resveratrol affects type II PtdIns 4-kinase activity but not PtdIns 3-kinase
activity. Recombinant type II PtdIns 4-kinase bwas purified from E. coli (a).
Human PtdIns 3 kinases were immunoprecipitated with anti p85 (b) and anti
p110 (c) subunits. All these enzymes were assayed for phosphatidylinositol
kinase activities as described in Section 2. 32P labeled products were
analyzed on tlc and the upper panel shows the autoradiogram. Lane 1:
enzyme activity in the absence of resveratrol. Lane 2: enzyme activity in
presence of 50 mM resveratrol. Lane 3: enzyme activity in presence of
100 mM resveratrol. The bar diagram depicts the quantification of the data.
Open bars: 0 mM resveratrol, hatch bars: 50 mM resveratrol, and cross-bars:
100 mM resveratrol. The values are mean of three experimentsS.E. The P
value is 0.002 (one-way ANOVA).recorded over a range of 340–500 nm using 320 nm as
excitation wavelength and fluorescence intensity at 389 nm
was used to calculate the dissociation constant.
The dissociation constant of resveratrol with type II
PtdIns 4-kinase b was determined by using ligand (resver-
atrol) titration procedure. Free resveratrol has a fluores-
cence maximum around 389 nm, upon binding to type II
PtdIns 4-kinase b the fluorescence intensity increases
several fold. Increased fluorescence of resveratrol at
389 nm, upon binding with type II PtdIns 4-kinase b
was used to determine the affinity of resveratrol and type
II PtdIns 4-kinase b interaction. Type II PtdIns 4-kinase b
(5 mM) was allowed to interact with different concentra-
tions of resveratrol (2–30 mM) in PBS at 25 8C. The
fluorescence intensity was measured at 389 nm upon bind-
ing. Buffer blank containing different concentrations of
resveratrol were subtracted from experimental data. DFm
(maximum fluorescence change when protein in comple-
tely liganded with resveratrol) was determined by plotting
1/C (resveratrol concentration) and 1/DF (increase in
fluorescence). The concentration of bound resveratrol
was calculated using the relationship, [bound ligand] = -
protein concentration  DF /DFm. The free resveratrol
concentration was calculated as [free resveratrol] = [total
resveratrol]  [bound resveratrol]. The dissociation con-
stant was calculated by plotting 1/[bound resveratrol] with
1/[free resveratrol] and calculating the slope [22].
2.8. Cell adhesion assay
Fibronectin (5 mg/ml) and matrigel (10 mg/ml) were
coated onto 96 well flat bottomed tissue culture plates
overnight at 37 8C and then the wells were blocked with
1% BSA in PBS for 1 h at 37 8C. Jurkat cells, suspended in
serum free RPMI, were pre-incubated with resveratrol
(100 mM) for 45 min at 37 8C. The treated cells were
washed with 0.1% BSA containing RPMI and resuspended
at a density of 3  105 cells/ml in 0.1% BSA containing
RPMI before addition to the plate. The Jurkat cells were
added to the well in 100 ml aliquot and incubated for
90 min at 37 8C. The non-adherent cells were washed
off with PBS by two rounds of gentle pipeting. To the
well 100 ml of serum containing RPMI was added with
final addition of 20 ml of MTT (1-(4,5-dimethylthiazol-2-
yl)-3,5-diphenylformazan) solution (5 mg/ml). The plates
were incubated at 37 8C for 12 h. The plates were cen-
trifuged at 7000  g for 30 min and supernatant was
removed. The formazan crystals were dissolved by addi-
tion of 100 ml of dimethylsulfoxide. Optical densities were
determined using an enzyme linked ImmunoSorbent
adsorption plate reader at 540 nm with 690 nm reference.
Background values were determined in wells coated with
1% BSA alone, were subtracted from each point. Adhesion
was expressed as a percentage of the respective total
number of cells (wells containing adherent and non-adher-
ent cells) [23].3. Results
3.1. Resveratrol inhibits human type II PtdIns 4-kinase
b in vitro
The effect of resveratrol on phosphoinositide kinases
was studied in vitro. Human type II PtdIns 4-kinase b was
expressed in E. coli as GST-fusion protein. The GST-tag
was removed and analyzed on SDS–PAGE (Fig. 1A). The
purified type II PtdIns 4-kinase b was assayed for activity
in presence of increasing concentrations of resveratrol.
PtdIns 4-kinase activity was inhibited by resveratrol in a
dose dependent fashion (Fig. 1B). To address whether this
inhibition is specific to type II PtdIns 4-kinase or not,
PtdIns 3-kinase activity was immunoprecipitated from
Jurkat cells with antibodies against p85 and p110 subunits
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Fig. 3. Resveratrol competes with phosphatidylinositol binding. Type II
PtdIns 4-kinase (5 mM) was incubated with increasing concentrations of
resveratrol (2–25 mM) in presence of varying concentrations of phospha-
tidylinositol. Fluorescence intensity at 389 nm was measured to calculate
the increase in resveratrol fluorescence upon protein binding. Increase inof PtdIns 3-kinase. Resveratrol did not inhibit PtdIns 3-
kinase activity in these immunoprecipitates while the same
concentrations of resveratrol showed a strong inhibition of
type II PtdIns 4-kinase activity (Fig. 1C). These results
suggest that type II PtdIns 4-kinases are selectively/pre-
ferentially inhibited by resveratrol.
3.2. Resveratrol competes with phosphatidylinositol
binding site on type II PtdIns 4-kinase b
To rule out any artifacts in resveratrol mediated inhibi-
tion of type II PtdIns 4-kinase activity, the direct interac-
tion of resveratrol with type II PtdIns 4-kinase was
addressed by fluorescence spectroscopic techniques. Incu-
bation of resveratrol with increasing concentrations of type
II PtdIns 4-kinase b showed an increase in resveratrol
fluorescence (Fig. 2A). The Kd value of the two molecules
was 7.2 mM (Fig. 2B). These results provide evidence for aFig. 2. Type II PtdIns 4-kinase b directly binds to resveratrol. Binding of
resveratrol to type II PtdIns 4-kinase was determined by fluorescence
spectroscopy. (A) Resveratrol (5 mM) was incubated with type II PtdIns
4-kinase b as described in experimental procedures, and the emission
spectra were collected after excitation at 320 nm. (1) Free resveratrol
(5 mM); (2) resveratrol (5 mM) incubated with 5 mM PtdIns 4-kinase;
and (3) resveratrol (5 mM) with 10 mM PtdIns 4-kinase. (B) Double
reciprocal plot for the binding of resveratrol to type II PtdIns 4-kinase
b. The fluorescence intensity at 389 nm was used to calculate the concen-
tration of bound and free resveratrol. The experiment is representative of
three experiments.
fluorescence was measured in absence of phosphatidylinositol (*), in
presence of 2 mM phosphatidylinositol (*), 5 mM PtdIns (~) and
20 mM PtdIns (~). Values are representative of four experiments.direct binding of resveratrol to type II PtdIns 4-kinase. The
binding of resveratrol to type II PtdIns 4-kinase b was not
affected by ATP (results not shown) but presence of
increasing concentrations of phosphatidylinositol abol-
ished resveratrol binding to type II PtdIns 4-kinase
(Fig. 3). These results suggest that resveratrol and phos-
phatidylinositol may compete for the same or overlapping
binding sites on the enzyme.
Kinetic analysis of the enzyme activity suggests that
resveratrol did not alter the Vmax of the enzyme but affected
its Km for phosphatidylinositol, supporting the hypothesis
that phosphatidylinositol and resveratrol compete for the
same site or an over lapping site (results not shown).
3.3. Resveratrol inhibits PtdIns 4-kinase activation in
Jurkat cells
The studies on in vitro inhibition of on type II PtdIns 4-
kinase activity by resveratrol was extended to cell culture
assays. Pre-incubation of Jurkat cells with increasing
concentrations of resveratrol showed a dose dependent
reduction in PtdIns 4-kinase activity (Fig. 4). Under these
experimental conditions resveratrol did not induce any cell
death as assayed by MTT (1-(4,5-dimethylthiazol-2-yl)-
3,5-diphenylformazan) or by trypan blue dye staining
methods, suggesting that the reduction in PtdIns 4-kinase
activity is not due to possible cytotoxic effects of resver-
atrol. Earlier studies from our lab and others have shown
activation of a type II PtdIns 4-kinase in Jurkat cells in
response to anti-CD3 cross-linking. Pre-incubation of Jur-
kat cells with resveratrol showed inhibition of type II
PtdIns 4-kinase activation in anti-CD3 stimulated cells,
suggesting that resveratrol interferes with type II PtdIns 4-
kinase functions (Fig. 5).
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Fig. 4. Resveratrol inhibits type II PtdIns 4-kinase activity in Jurkat cells.
Jurkat cells were incubated with increasing concentration of resveratrol for
45 min at 37 8C. At the end of incubation, cells were washed and were lysed
in lysis buffer. Cell lysates were assayed for PtdIns 4-kinase activity. The
upper panel shows autoradiograph of PtdIns 4P formed and the line diagram
shows the quantification of the data. Values are representative of three
experiments. Error bars represent S.D.3.4. Resveratrol inhibits Jurkat cell adhesion
T lymphocytes need to adhere to the extra cellular
matrix molecules like fibronectin, laminin and collagen
at the site of inflammation. Type II PtdIns 4-kinases are
shown to be associated with integrin receptors and areFig. 5. Resveratrol inhibits type II PtdIns 4-kinase activation in anti-CD3
stimulated Jurkat cells. Jurkat cells were pre treated with resveratrol
(100 mM) and stimulated with anti-CD3 crosslinking. The cells were lysed
and assayed for PtdIns 4-kinase activity. Lane 1: lysates from control cells
(absence of resveratrol treatment and CD3 cross linking). Lane 2: lysates
from CD3 cross linked cells in the absence of resveratrol. Lane 3: lysates
from cells pre-incubated with resveratrol (100 mM) in absence of CD3 cross
linking. Lane 4: cell lysates from cells pre-treated with resveratrol
(100 mM) followed by CD3 cross linking. Graph shows mean  S.E. of
four experiments. The P value is 0.0015 (one-way ANOVA).suggested to play a role in cell adhesion and motility [24].
The effect of resveratrol on cell adhesion was analyzed
with Jurkat cells on two extra cellular matrix substrates,
viz. fibronectin and matrigel. Resveratrol inhibited the
adhesion of Jurkat cells on both these substrates. A
50% decrease in adhesion of Jurkat cells was observed
in fibronectin coated plates (Fig. 6A), while a 70%
decrease in cell adhesion was observed in matrigel coated
plates (Fig. 6B). These results support the hypothesis that
type II PtdIns 4-kinase activity is necessary for cell adhe-
sion and resveratrol negatively modulates cell adhesion by
inhibiting the enzyme activity.
The role of type II PtdIns 4-kinase in cell adhesion was
addressed in parallel experiments in which PtdIns 4-kinaseFig. 6. Resveratrol affects Jurkat cell adhesion. Jurkat cells were pre-treated
with resveratrol (100 mM) and PAO (20 mM) and checked for adhesion on
matrigel coated plates (A) and on fibronectin coated plates (B). Cell
adhesion was assayed using MTT method. The graph represents percentage
of adherent cells in comparison to control (untreated cells) taken as 100%.
Values are representative of six experimentsS.E. The P values are0.003
(one-way ANOVA).
1053activity was inhibited with phenylarsine oxide (PAO). Pre-
treatment of Jurkat cells with PAO showed60% decrease
in cell adhesion in matrigel coated plates. These studies
suggest that type II PtdIns 4-kinases can be potential
targets for pharmacological intervention in treatment of
inflammation and cancer metastasis.4. Discussion
Type II PtdIns 4-kinase(s), in addition to their role in
biosynthesis of PtdIns(4,5)P2, are also implicated in other
physiological functions like cytoskeletal rearrangement,
intracellular vesicular transport, cell secretion and mitogen-
esis [15,25–27]. Nonavailability of inhibitors for type II
PtdIns 4-kinases makes it difficult to assess their individual
contributions in these signaling cascades. The present manu-
script describes resveratrol as an inhibitor for type II PtdIns
4-kinases and suggests its use as a pharmacological tool to
distinguish type II PtdIns 4-kinase signaling cascades from
PtdIns 3-kinase pathways. This suggestion is supported by
the following observations: (a) it showed dose dependent
inhibition of type II PtdIns 4-kinase b isoform activity in in
vitro assays, while the same concentrations have no sig-
nificant effects on PtdIns 3-kinase activity, (b) it binds to
type II PtdIns 4-kinase b as shown by fluorescence spectro-
scopic studies, (c) resveratrol is a competitive inhibitor of
PtdIns, and (d) resveratrol showed a dose dependent inhibi-
tion of type II PtdIns 4-kinase activity in Jurkat cells.
Resveratrol did not inhibit yeast PtdIns 4-kinase PIK (a
homologue of type III PtdIns 4-kinases, which share homol-
ogy with PtdIns 3-kinase) under these experimental condi-
tions (results not shown). These results strongly support that
resveratrol inhibits type II PtdIns 4-kinase activity and can
discriminate over PI 3-kinase signaling pathways.
In addition to type II PtdIns 4-kinases, resveratrol has
been shown to bind and inhibit cyclooxygenases, protein
kinase C and transcriptional factor NF-kB [6,12,28–31].
Even though PKC is activated by pharmacological agent
PMA in vivo, PtdIns (4,5)P2 is implicated as the physiolo-
gical ligand for PKC [32–34]. PtdIns (4,5)P2 is suggested to
be a competitor for PMA binding on PKC [32–34]. The
binding sites of resveratrol on protein kinase C are in the
region where PMA binds [12]. It would be interesting to
know whether resveratrol mediated inhibition of PKC may
be due to its competition with PtdIns (4,5)P2 binding in vivo.
Resveratrol has been implicated in PtdIns 3-kinase
mediated signaling cascades [35,36]. The concentrations
required for inhibition of PtdIns 3-kinase is significantly on
the higher side compared to our studies. It could be
possible that inhibition of type II PtdIns 4-kinases at these
concentrations may limit the synthesis of PtdIns 4P and
subsequent productions of PtdIns (3,4)P2 or PtdIns
(3,4,5)P3. and activation of Akt/PKB pathways.
Recently Haider et al. have reported that resveratrol may
not inhibit PtdIns 3-kinase activity per se but affectsupstream of PtdIns 3-kinase signaling cascades in vascular
smooth muscle cells. Resveratrol is shown to activate
Shp2, a phosphotyrosine phosphatase in vascular smooth
muscle cells. Activation of Shp2 leads to dephosphoryla-
tion of adaptor molecule Gab 1 and prevents Gab 1/PtdIns
3-kinase interaction thus attenuating PtdIns 3-kinase sig-
naling cascades [37]. Further, serum-induced PtdIns 3-
kinase signaling pathways are not inhibited by resveratrol,
supporting that resveratrol affects PtdIns 3-kinase signal-
ing pathways by indirect means. These results are in
support of present observations, in which we demonstrated
that resveratrol does not inhibit PtdIns 3-kinase activity. In
addition to its direct effects on type II PtdIns 4-kinase,
resveratrol may also negatively modulate PtdIns 4-kinase
signaling events through Shp2. Type II PtdIns 4-kinase
activity in rat splenic cells has been shown to increase upon
tyrosyl phosphorylation [18,19]. While p56lck has been
implicated in phosphorylation of type II PtdIns 4-kinases,
phosphatase(s) responsible for dephosphorylation were not
identified. It would be interesting to know whether Shp2
can be a potential regulator of type II PtdIns 4-kinases.
Resveratrol is known to inhibit cell proliferation and
induce apoptosis in cancer cells. Cellular proliferation
involves the stimulation of mitogen activated protein
kinase (MAPK) pathway, and the PtdIns 3-kinase pathway
consisting of PI3K/phosphoinositide-dependent kinase 1
(PDK1)/Akt cascade. Both MAPK and PDK1 affect cell
division by regulating multiple cyclin dependent kinases
[38–43]. Inhibition of type II PtdIns 4-kinase by resveratrol
may down regulate PtdIns 4P levels which are substrates
for PtdIns 3-kinases thus affecting PI3K/PDK1/Akt cas-
cade. Recently, a type III PtdIns 4-kinase (PI4K92) has
been shown to have potential cdc 2 phosphorylation sites,
which suggest a role of these kinases in rearrangement of
the Golgi apparatus during cell division [44]. These studies
suggest that phosphatidylinositol 4-kinases may play a role
in cell division at different levels.
Inhibition of type II PtdIns 4-kinase activity in Jurkat cells
by resveratrol suggests that resveratrol can be used as
pharmacological tool to address the role of PtdIns 4-kinase
signaling cascades. Type II PtdIns 4-kinases are shown to
associate with integrin molecules and are implicated in cell
adhesion [24]. Cell adhesion plays a major role in lympho-
cyte migration to sites of inflammation and also in metastasis
of tumor cells. Inhibition of Jurkat cell adhesion to fibro-
nectin coated surfaces by resveratrol with a concomitant
reduction in PtdIns 4-kinase activity strongly correlates with
a regulatory role for type II PtdIns 4-kinases in lymphocyte
infiltration and a possible role in tumor metastasis.Acknowledgements
We thank Prof. G. Krishnamoorthy, Department of
Chemical Sciences, Tata Institute of Fundamental
Research, Mumbai, India for his help with fluorescence
1054spectrophotometric studies and Prof. T. Balla, Endocrinol-
ogy and Reproduction Research Branch, NICHD,
Bethesda, MD, USA, for his generous gift of human type
II PtdIns 4-kinase b clone. This research work was sup-
ported by grants in aid from Council of Scientific and
Industrial Research (sanction no.: 37 (1099)02/EMR-II)
and Board of Research in Nuclear Sciences Government of
India (sanction no.: 2003/37/5/BRNS/667) to Prof. G.
Subrahmanyam. Mrs. Rupa Srivastava is supported by
CSIR-SRF.References
[1] Langcake P, Pryce RJ. A new class of phytoalexins from grapevines.
Experientia 1977;33:151–2.
[2] Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et
al. Cancer chemo preventive activity of resveratrol, a natural product
derived from grapes. Science 1997;275:218–20.
[3] Fre´mont L. Biological effects of resveratrol. Life Sci 2000;66:663–73.
[4] Pezzuto JM. Resveratrol: a whiff that induces a biologically specific
tsunami. Cancer Biol Ther 2004;3:889–90.
[5] Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ.
Mechanism of cardio protection by resveratrol, a phenolic antioxidant
present in red wine. Int J Mol Med 2001;8:3–17.
[6] Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resver-
atrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett
1998;421:277–9.
[7] Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati
G, et al. Resveratrol arrests the cell division cycle at S/G2 phase
transition. Biochem Biophys Res Commun 1998;250:53–8.
[8] Haworth RS, Avkiran M. Inhibition of protein kinase D by resveratrol.
Biochem Pharmacol 2001;62:1647–51.
[9] Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol
causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and
induction of apoptosis in human epidermoid carcinoma A431 cells.
Clin Cancer Res 2001;7:1466–73.
[10] Wolter F, Akoglu B, Clausnitzer A, Stein J. Downregulation of the
cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle
arrest in colon cancer cell lines. J Nutr 2001;131:2197–203.
[11] Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol.
Ann N Y Acad Sci 2002;957:210–9.
[12] Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ. Inhibition of
protein kinase C by resveratrol. Biochim Biophys Acta 2003;1637:59–
69.
[13] Wang Y, Wang B, Cheng J, Yang L, Liu ZL, Balan K, et al. FADD-
dependent apoptosis induction in Jurkat leukemia T-cells by the
resveratrol analogue, 3,4,5-trihydroxy-trans-stilbene. Biochem Phar-
macol 2005;69:249–54.
[14] Hsieh T, Halicka D, Lu X, Kunicki J, Guo J, Darzynkiewicz Z, et al.
Effects of resveratrol on the G(0)–G(1) transition and cell cycle
progression of mitogenically stimulated human lymphocytes. Bio-
chem Biophys Res Commun 2002;297:1311–7.
[15] Balla T. Pharmacology of phosphoinositides, regulators of multiple
cellular functions. Curr Pharm Des 2001;7:475–7.
[16] Heilmeyer Jr LM, Vereb Jr G, Vereb G, Kakuk A, Szivak I. Mamma-
lian phosphatidylinositol 4-kinases. IUBMB Life 2003;55:59–65.
[17] Fernandis AZ, Subrahmanyam G. Concanavalin A modulates tyrosine
phosphorylation and activation of a type II phosphatidylinositol 4-
kinase in rat splenic lymphocytes. Mol Immunol 1998;35:935–41.
[18] Fernandis AZ, Subrahmanyam G. Protein tyrosine phosphorylation
activates rat splenic type II phosphatidylinositol 4-kinase in vitro.
FEBS Lett 1998;441:432–6.[19] Fernandis AZ, Subrahmanyam G. Tyrosyl phosphorylation and acti-
vation of a type II phosphatidylinositol 4-kinase by p56(lck) in
Concanavalin A stimulated rat splenic lymphocytes. Mol Immunol
2000;37:273–80.
[20] Fernandis AZ, Srivastava R, Sinha RK, Subrahmanyam G. A type II
phosphatidylinositol 4-kinase associates with T cell receptor zeta
chain in Con A stimulated splenic lymphocytes through tyrosyl
phosphorylation-dependent mechanisms. Mol Immunol 2005;42:
561–8.
[21] Srivastava R, Sinha KR, Subrahmanyam G. Type II PtdIns 4-kinase b
interacts with TCR-CD3 zeta chain. Mol Immunol, 2005, doi:10.1016/
j.molimm.2005.03.009.
[22] Santra MK, Panda D. Detection of an intermediate during unfolding of
bacterial cell division protein FtsZ: loss of functional properties
precedes the global unfolding of FtsZ. J Biol Chem
2003;278:21336–43.
[23] Gude RP, Binda MM, Presas HL, Klein-Szanto AJ, Bonfil RD. Studies
on the mechanisms responsible for inhibition of experimental metas-
tasis of B16-F10 murine melanoma by pentoxifylline. J Biomed Sci
1999;6:133–41.
[24] Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME. A
novel link between integrins, transmembrane-4 superfamily proteins
(CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem
1997;272:2595–8.
[25] Barkalow K, Witke W, Kwiatkowski DJ, Hartwig JH. Coordinated
regulation of platelet actin filament barbed ends by gelsolin and
capping protein. J Cell Biol 1996;134:389–99.
[26] Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell
Biol 1996;8:153–8.
[27] Auger KR, Cantley LC. Novel polyphosphoinositides in cell growth
and activation. Cancer Cells 1991;3:263–70.
[28] Garcia-Garcia J, Micol V, de Godos A, Gomez-Fernandez JC. The
cancer chemopreventive agent resveratrol is incorporated into model
membranes and inhibits protein kinase C alpha activity. Arch Biochem
Biophys 1999;372:382–8.
[29] Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Per-
spect 2003;16:299–307.
[30] Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, et al.
Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synth-
esis and structure-activity relationship. Bioorg Med Chem
2004;12:5571–8.
[31] Kundu JK, Surh YJ. Molecular basis of chemoprevention by resver-
atrol: NF-kappaB and AP-1 as potential targets. Mutat Res
2004;555:65–70.
[32] Quest AF, Bell RM. The regulatory region of protein kinase C gamma.
Studies of phorbol ester binding to individual and combined functional
segments expressed as glutathione S-transferase fusion proteins indi-
cate a complex mechanism of regulation by phospholipids, phorbol
esters, and divalent cations. J Biol Chem 1994;269:20000–2.
[33] Quest AF, Bardes ES, Bell RM. A phorbol ester binding domain of
protein kinase C gamma. Deletion analysis of the Cys2 domain defines
a minimal 43-amino acid peptide. J Biol Chem 1994;269:2961–70.
[34] Singh SS, Chauhan A, Brockerhoff H, Chauhan VP. Interaction of
protein kinase C and phosphoinositides: regulation by polyamines.
Cell Signal 1994;6:345–53.
[35] Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM.
Resveratrol suppresses angiotensin II-induced Akt/protein kinase B
and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat
aortic smooth muscle cells. Mol Pharmacol 2002;62:772–7.
[36] Pozo-Guisado E, Lorenzo-Benayas MJ, Fernandez-Salguero PM.
Resveratrol modulates the phosphoinositide 3-kinase pathway through
an estrogen receptor alpha-dependent mechanism: relevance in cell
proliferation. Int J Cancer 2004;109:167–73.
[37] Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling
KK, et al. Resveratrol inhibits angiotensin II- and EGF-mediated Akt
activation role of Gab 1 and Shp2. Mol Pharmacol 2005;68:41–8.
1055[38] Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon
M. Cooperative regulation of the cell division cycle by the
protein kinases RAF and AKT. Mol Cell Biol 2004;24:
10868–81.
[39] Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, et al. G1 cell
cycle progression and the expression of G1 cyclins are regulated by
PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Am J Physiol Cell Physiol 2004;287:C281–91.
[40] Cory AH, Somerville L, Cory JG. Blockage of cyclin cdk’s, PKC and
phosphoinositol 3-kinase pathways leads to augmentation of apoptosis
in drug-resistant leukemia cells: evidence for interactive effects of
flavopiridol LY 294002 roscovitine, wortmannin and UCN-01. Antic-
ancer Res 2005;25:101–6.[41] Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R,
et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle
arrest in anaplastic large cell lymphoma. Blood 2005;105:827–9.
[42] Blenis J. Signal transduction via the MAP kinases: proceed at your
own RSK. Proc Natl Acad Sci USA 1993;90:5889–92.
[43] Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frodin
M. 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-
phosphoinositide-dependent protein kinase-1. J Biol Chem
1999;274:27168–76.
[44] Suer S, Sickmann A, Meyer HE, Herberg FW, Heilmeyer Jr LM.
Human phosphatidylinositol 4-kinase isoform PI4K92. Expression of
the recombinant enzyme and determination of multiple phosphoryla-
tion sites. Eur J Biochem 2001;268:2099–106.
